Company / R&D Expense
Denali Therapeutics Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$418.8M
FY2025
5-year range
$193.4M / $423.9M
FY2021-FY2025
Trend
+5.6%
vs FY2024
Sector context
#41 of 210
Health Care
What the data says
Denali Therapeutics Inc.'s r&d expense of $419M is higher than 80% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $74M in FY2019 to $424M in FY2023.
Based on SEC 10-K filings.
$419M in FY2025 with a 5-year CAGR of +23.9%. Top quartile in the Health Care sector.
Remained stable around $419M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +25.4%
- 5-Year CAGR
- +23.9%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 210This company $418.8M Sector average $644.0M
▼
-35.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.9%, indicating consistent growth.
- In FY2025, r&d expense increased 5.6% year-over-year.
- Ranks #41 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $418.8M | +5.6% |
| FY2024 | $396.4M | -6.5% |
| FY2023 | $423.9M | +99.4% |
| FY2022 | $212.6M | +9.9% |
| FY2021 | $193.4M | +35.1% |
| FY2020 | $143.2M | +92.3% |
| FY2019 | $74.5M | -1.6% |
| FY2018 | $75.7M | +1.7% |
| FY2017 | $74.5M | -1.6% |
| FY2016 | $75.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026